EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer

Published:2013-11 Issue:14 Volume:14 Page:1765-1777
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

de Mello Ramon Andrade¹,Madureira Pedro²³,Carvalho Liliana S³⁴,Araújo António⁵²,O’Brien Mary⁶,Popat Sanjay⁶⁷

Affiliation:

1. Department of Medicine, Faculty of Medicine, University of Porto (FMUP), Alameda Prof Hernani, Monteiro, 4200-319, Porto, Portugal.

2. ICBAS – Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal

3. IBMC – Instituto de Biologia Molecular e Celular, Porto, Portugal

4. Department of Pharmacology & Therapeutics, FMUP – Faculty of Medicine, University of Porto, Alameda Prof Hernani Monteiro, 4200-319, Porto, Portugal

5. Department of Medical Oncology, Portuguese Oncology Institute, Rua Dr António Bernardino de Almeida, 4200-072, Porto, Portugal

6. Department of Medicine, Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK

7. Molecular Genetics & Genomics Group, Imperial College, London, UK

Abstract

Personalized therapy has significantly developed in lung cancer treatment over recent years. VEGF and EGF play a major role in non-small-cell lung cancer (NSCLC) tumor angiogenesis and aggressiveness. EGFR mutation as well as KRAS and ALK rearrangements are important biomarkers in the field owing to potential targeted therapies involved in clinical practice: erlotinib, geftinib, cetuximab and crizotinib. More recently, regulation of tumor immunity through CTLA4 and PD1/L1 has emerged as a promising field in NSCLC management. This review will focus on the current and future biomarkers in the advanced NSCLC field and also address potential related targeted therapies for these patients.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.13.177

Reference130 articles.

1. Global cancer statistics

2. Cancer statistics, 2012

3. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)

4. Lung Cancer

5. Personalizando a medicina – estratégias para implementar a avaliação do rearranjo do ‘anaplastic lymphoma kinase’ no carcinoma do pulmão de não pequenas células em Portugal

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multisequence MRI-based radiomics signature as potential biomarkers for differentiating KRAS mutations in non-small cell lung cancer with brain metastases;European Journal of Radiology Open;2024-06

2. Inhibin βA is an independent prognostic factor that promotes invasion via Hippo signaling in non‑small cell lung cancer;Molecular Medicine Reports;2021-09-09

3. Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study;Lung Cancer;2020-09

4. Nuances to precision dosing strategies of targeted cancer medicines;Pharmacology Research & Perspectives;2020-07-13

5. Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro;Anti-Cancer Drugs;2019-06